Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LT-02
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Nestle Health Sciences SA | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LT-02 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 29, 2016
Lead Product(s) : LT-02
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Nestle Health Sciences SA | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aldesleukin
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Ahmad Tarhini
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aldesleukin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 10, 2016
Lead Product(s) : Aldesleukin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Ahmad Tarhini
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crown Protein
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Nestle Health Sciences SA | Nestec
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Crown Protein is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 08, 2016
Lead Product(s) : Crown Protein
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Nestle Health Sciences SA | Nestec
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin-2
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interleukin-2 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft vs Host Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 19, 2015
Lead Product(s) : Interleukin-2
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin-2
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : UT Southwestern Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
Details : Interleukin-2 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 11, 2013
Lead Product(s) : Interleukin-2
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : UT Southwestern Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vemurafenib
Therapeutic Area : Oncology
Study Phase : Phase IV
Recipient : Clinigen Group
Deal Size : Inapplicable
Deal Type : Inapplicable
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Details : Vemurafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2012
Lead Product(s) : Vemurafenib
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Recipient : Clinigen Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Leonard Appleman
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2012
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Leonard Appleman
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Study Phase : Undisclosed
Recipient : Shradha Agarwal
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Remicade is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 21, 2011
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Recipient : Shradha Agarwal
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IL-2` is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 15, 2011
Reset All
